摘要 |
Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating pulmonary arterial hypertension. More particularly, aspects of the present invention are related to using a combination of iloprost and at least one additional agent, selected from the group consisting of an endothelin receptor antagonist and a PDE inhibitor.
|